Assessing clinical response and defining minimal disease activity in plaque psoriasis with the Physician Global Assessment and body surface area (PGA × BSA) composite tool: An analysis of apremilast phase 3 ESTEEM data - 23/11/17
Sponsored by Celgene Corporation, Summit, New Jersey. |
|
Disclosure: Dr Gottlieb has consulting/advisory board agreements with Amgen, Astellas, Akros, Centocor (Janssen), Celgene Corporation, Bristol-Myers Squibb, Beiersdorf, Abbott Labs (AbbVie), TEVA, Actelion, UCB, Novo Nordisk, Novartis, Dermipsor Ltd, Incyte, Pfizer, Can-Fite, Lilly, Coronado, Vertex, Karyopharm, CSL Behring Biotherapies for Life, GlaxoSmithKline, XenoPort, Catabasis, Meiji Seika Pharma Co, Takeda, Mitsubishi Tanabe Pharma Development America, Genentech, Baxalta, Kineta One, KPI Therapeutics, Crescendo Bioscience, Aclaris, Amicus, Sun Pharma, Dr Reddy's Laboratories, Valeant, and Dermira, and she is the recipient of research/educational grants paid to Tufts Medical Center from Centocor (Janssen), Amgen, Abbott (AbbVie), Novartis, Celgene Corporation, Pfizer, Lilly, Levia, Merck, XenoPort, Dermira, and Baxalta. Dr Merola has been a consultant, investigator, and/or advisory board member for, and/or has received grants and/or honoraria from AbbVie, Amgen, Biogen Idec, Celgene Corporation, Centocor/Janssen, Eli Lilly, Janssen, Momenta, Novartis, and Pfizer. Dr Chen was employed by Celgene Corporation at the time of study conduct. Dr Levi is an employee of Celgene Corporation. Dr Duffin has been a consultant, steering committee member, and/or advisory board member for, and/or has received grants and/or honoraria from AbbVie, Amgen, Boehringer Ingelheim, Bristol-Myers Squibb, Celgene Corporation, Centocor/Janssen, Eli Lilly, Novartis, Pfizer, Regeneron, Stiefel, and XenoPort. |
|
Reprints not available from the authors. |
Vol 77 - N° 6
P. 1178-1180 - décembre 2017 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?